Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil H Bander

Showing results (31-40 of 85) with videos related to

Pageof 9
Sort By:
The Prostate|March 24, 2023
Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literatureJudith Stangl-Kremser, Andres Ricaurte-Fajardo, Kritika Subramanian, et al.
Molecular Biology of the Cell|October 7, 2003
A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigenSigrid A Rajasekaran, Gopalakrishnapillai Anilkumar, Eri Oshima, et al.
The Journal of Urology|November 12, 2003
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigenDavid M Nanus, Matthew I Milowsky, Lale Kostakoglu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2005
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigenShankar Vallabhajosula, Stanley J Goldsmith, Klaus A Hamacher, et al.
Current Radiopharmaceuticals|March 16, 2015
Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal AntibodyShankar Vallabhajosula, Anastasia Nikolopoulou, Yuliya S Jhanwar, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 25, 2011
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigenMichael J Evans, Peter M Smith-Jones, John Wongvipat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2007
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumorsMatthew I Milowsky, David M Nanus, Lale Kostakoglu, et al.
The Prostate|March 18, 2003
Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell lineJason J Christiansen, Sigrid A Rajasekaran, Peggy Moy, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|December 6, 2013
Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancersAlla Gabriella Wernicke, Sonal Varma, Eleni A Greenwood, et al.
Cancer|February 4, 2010
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancerScott T Tagawa, Himisha Beltran, Shankar Vallabhajosula, et al.
Pageof 9

Showing results (31-40 of 85) with videos related to

Sort By:
Pageof 9
The Prostate|March 24, 2023
Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literatureJudith Stangl-Kremser, Andres Ricaurte-Fajardo, Kritika Subramanian, et al.
Molecular Biology of the Cell|October 7, 2003
A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigenSigrid A Rajasekaran, Gopalakrishnapillai Anilkumar, Eri Oshima, et al.
The Journal of Urology|November 12, 2003
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigenDavid M Nanus, Matthew I Milowsky, Lale Kostakoglu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2005
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigenShankar Vallabhajosula, Stanley J Goldsmith, Klaus A Hamacher, et al.
Current Radiopharmaceuticals|March 16, 2015
Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal AntibodyShankar Vallabhajosula, Anastasia Nikolopoulou, Yuliya S Jhanwar, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 25, 2011
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigenMichael J Evans, Peter M Smith-Jones, John Wongvipat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2007
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumorsMatthew I Milowsky, David M Nanus, Lale Kostakoglu, et al.
The Prostate|March 18, 2003
Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell lineJason J Christiansen, Sigrid A Rajasekaran, Peggy Moy, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|December 6, 2013
Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancersAlla Gabriella Wernicke, Sonal Varma, Eleni A Greenwood, et al.
Cancer|February 4, 2010
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancerScott T Tagawa, Himisha Beltran, Shankar Vallabhajosula, et al.
Pageof 9